Evaluating a patented fatty acid and PEA formulation in patients with chemotherapy-induced peripheral neuropathy.
146
Patients
Multi-center
Observational
3 months
Evaluation
Peer-reviewed
Published
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common — and least addressed — long-term side effects of cancer treatment. Many patients live with tingling, burning, numbness, and balance changes for months or years after their treatment ends.
Despite the prevalence of CIPN, few interventions have meaningful evidence. The STEFANO investigators set out to evaluate whether a patented combination of specific fatty acids and PEA — chosen for their roles in supporting nerve membranes, myelin, and inflammatory balance — could meaningfully affect patient-reported sensory and motor neuropathy.
A multi-center observational study evaluated patients over a three-month period. Sensory and motor neuropathy were assessed at baseline, monthly during the evaluation, and at follow-up.
Multi-center
Multiple clinical sites
Observational
Real-world conditions
3 months
Evaluation period
146 patients experiencing CIPN after cancer treatment were enrolled. Patients reflected a real-world mix of prior chemotherapy regimens and neuropathy severity.
146 patients
Enrolled across multiple centers, all experiencing chemotherapy-induced peripheral neuropathy after completion of cancer treatment.
Sensory neuropathy
Tingling, burning, numbness, sensitivity to temperature
Motor neuropathy
Weakness, fine motor coordination, balance
Symptom trajectory
Change over baseline → month 3
Stabilization
Maintenance of function over time
Researchers observed improvements and stabilization of sensory and motor neuropathy symptoms in many patients following three months of use. Patient-reported outcomes captured changes in everyday function alongside clinical measures.
Conceptual symptom trajectory
Illustrative direction of change observed in many patients over the three-month evaluation.
Visual illustration of observed group-level direction of change. Refer to the published study for full data.
The STEFANO study supports the role of a patented fatty acid + PEA formulation as part of a science-informed approach to supporting nerve health in patients experiencing CIPN. Findings suggest that consistent use over a three-month evaluation period can be associated with meaningful patient-reported improvements.
In summary
Many patients reported improvements and stabilization of sensory and motor neuropathy symptoms after three months.